GlaxoSmithKline Reveals Ingenuity

GlaxoSmithKline Reveals Ingenuity
In a further validation of Big Pharma�s acceptance of systems biology, GlaxoSmithKline has licensed part of the Ingenuity Pathways Knowledge Base to facilitate genome-wide computational analysis of biological systems underlying disease.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.